Synopsis
In this fireside chat hosted at Emulate headquarters on February 10, 2026, leaders from industry discuss current strategies for leveraging NAMs and the future outlook for these approaches in drug development. The discussion covers topics such as regulatory momentum, integration of complex in vitro and computational models, scaling through automation, and what pharma teams should be prioritizing over the next several years.
Speakers include:
- Sam Michael, PhD, VP of Data, Automation, and Predictive Sciences at GSK
- Ajay Yekkirala, PhD, Co-Founder & CSO of Superluminal Medicines
- Rhiannon Hardwick, PhD, DABT, Scientific Director of Discovery Toxicology at Bristol Myers Squibb